top of page


Current research and developmental goal of MIGRA-Therapeutics, LLC, include conducting preclinical development and validation of targeted drug delivery platforms and corresponding therapeutic agents for targeted therapy of advanced and drug resistant human cancer.  With funding support from the National Institutes of Health SBIR phase I/II, Georgia Research Alliances, and a joint effort of Dr. Yang’s research lab at the Winship Cancer Institute of Emory University, research activities of MIGRA-Therapeutics, LLC are focused on the following two areas:

MIGRA - Chemotherapy Drug Delivery Platform

Investigational New Drug (IND)-enabling preclinical studies for the development of a targeted and stroma penetrating nanoparticle drug, MIGRA-NP01, into a phase 1 clinical trial for  pancreatic cancer therapy


MIGRA - Cell Delivery Platform

Targeted cancer immunotherapy using a receptor targeted and tumor stroma-penetrating ligand to direct efficient delivery of therapeutic T cells, CAR T cells, NK cells, or Gamma-delta (γδ) T cells in human solid tumors.

thumbnail_IMG_4496 1.jpg

MIGRA Drug Delivery System

Hyaluronic Acid Nanoparticle

We use specific hyaluronic acid nanoparticles that have a natural affinity for receptors found on cancer cells. This is only one part of our targeted delivery system.


A protease with extracellular matrix degradative abilities that allow us to penetrate further into solid tumors. When paired with plasminogen activators, the protease becomes specific for receptors found on tumor stromal cells.

MIGRA-Chemotherapy Drug Delivery Platform

Chemotherapy drugs

SN-38 is an effective topoisomerase I inhibitor, effectively halting the tumor reproduction cycle.

MIGRA-Cell Delivery Platform

Therapeutic Cells

CAR-T cells are engineered for specific cancers. With their artificial receptors, they are designed to attack specific proteins.

MIGRA-Therapeutics, LLC, also has several preclinical pipeline projects for future clinical translation as targeted cancer imaging and therapeutic agents. The platform technologies developed by our research team have the potential for broad applications in the field of drug and gene delivery for oncology and non-oncological diseases. We are seeking potential collaborations with academic investigators, biotech and pharmaceutical company partners, and investors to accelerate the process of clinical translation.  

bottom of page